ArticleDrugs - real world outcomes2026
Trends in First-Time Symptomatic Antidementia Drug Dispensations to Home-Dwelling People in Norway: A Nationwide Register-Based Study.
Article in Drugs - real world outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundSymptomatic antidementia drugs can influence cognitive symptoms. According to Norwegian dementia guidelines, general practitioners (GPs) are responsible for assessing, treating, and following up on dementia, with extended assessments provided by specialist healthcare in more complicated cases and for patients under 65 years of age.
objectiveThe aim of this study was to investigate trends in first-time antidementia drug dispensations to home-dwelling people aged 60 years and older in Norway (2006-2020), and to analyse whether a GP issued the first prescription.
methodsThis repeated annual cross-sectional study utilized data from the Norwegian Prescribed Drug Registry (NorPD). Age- and sex-stratified incidence rates of antidementia drugs (ATC N06D) dispensed by Norwegian pharmacies between January 1, 2006, and December 31, 2020, were analysed. The Norwegian GP Registry was linked with NorPD to identify if the prescriber worked as a GP at the time of the first antidementia prescription.
resultsIn this study, 66,886 individuals received a novel antidementia drug dispensation. The incidence rates of first-time antidementia drug dispensations showed an overall declining trend during the study period. Females accounted for 61.1% of first-time dispensations, with the highest incidence rates observed in the 80-84-years age group across both sexes. Across all age groups, female patients were more likely than male patients to receive their first antidementia prescription from a GP. Patient age had a notable influence on prescriber type, with older people more often receiving their first prescription from a GP compared with younger people.
conclusionsThere was a declining trend in the annual incidence rate of antidementia drug dispensations to home-dwelling people. Older age and female sex were associated with an increased likelihood of receiving a first-time symptomatic antidementia drug prescription from a GP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.